Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

MCLEAN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (TLI), a not-for-profit organization that works at the nexus of science, ...

Our eyesight is essential to getting around, but if you’re not careful it can be seriously challenged by age-related macular ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic macular edema with ...

According to the Centers for Disease Control and Prevention, in 2019 an estimated 19.8 million Americans 40 years and older were living with age-related macular degeneration. “It’s more likely ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

“I am excited to offer Susvimo to my patients living with diabetic macular edema who want an option with longer ... “Having completed dozens of Susvimo surgeries in my patients with wet, or ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

The goal is to educate the public and professionals about AMD and support patients and families affected by vision impairment ...